Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy 6-8 months old infants~Exclusion Criteria:~* previous receipt of any meningococcal B vaccine;~* previous ascertained or suspected disease caused by N meningitidis;~* history of any anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or known hypersensitivity to any vaccine component;~* any present or suspected serious acute or chronic disease~* known or suspected autoimmune disease or impairment /alteration of immune function

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 8 Months
- Healthy Volunteers: t

Study Arms:
- rMenB (Type: EXPERIMENTAL): 6-8 months-old infants received 3 doses of rMenB vaccine without OMV-NZ at 6-8 months of age, 2 months later and 12 months of age.
- rMenB+OMV (Type: EXPERIMENTAL): 6-8 months-old infants received 3 doses of rMenB vaccine with OMV-NZ at 6-8 months of age, 2 months later and 12 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).